NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Protara Therapeutics announced promising results from its Phase 2 ADVANCED-2 trial for TARA-002, an investigational therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study shows a ...

The potential of disitamab vedotin in bladder preservation during neoadjuvant therapy for bladder cancer: A comparative analysis with the GC regimen. OS and PFS estimates of NAC regimen in stage ...

Stage 2 pancreatic cancer includes stages 2A and 2B. Stage 2A is when the cancer tumor has grown to over 4 centimeters (cm). Stage 2B is when it has spread from the pancreas to up to three nearby ...

Johnson & Johnson (NYSE:JNJ) said it has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder cancer, or MIBC, due to disappointing data. The drugmaker had ...

In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event ...

Stage 2 Hodgkin’s lymphoma is an early stage of this cancer. Healthcare professionals describe Hodgkin’s lymphoma as stage 2 when a person has cancer in two or more lymph node groups, either below or ...